Rilpivirine exposure in plasma and sanctuary site compartments after switching from nevirapine-containing combined antiretroviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1642-1647

  Mora Peris, Borja ^a,b   Watson, Victoria ^c   Vera, Jaime H ^a,b   Weston, Rosy ^b   Waldman, Adam D ^a   Kaye, Steve ^a   Khoo, Saye ^c   Mackie, Nicola E ^a,b   Back, David ^c   Winston, Alan ^a,b  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b IMPERIAL COLLEGE HEALTHCARE NHS TRUST   (United Kingdom)

^c UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

CSF; Nevirapine; Seminal plasma; Switch

Indexed keywords

ANTIRETROVIRUS AGENT; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITAINE PLUS NEVIRAPINE PLUS TENOFOVIR; NEVIRAPINE; RILPIVIRINE; UNCLASSIFIED DRUG; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; NITRILE; PYRIMIDINE DERIVATIVE;

ADULT; ARTICLE; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG EXPOSURE; DRUG PROTEIN BINDING; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; SEMINAL PLASMA; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; DRUG EFFECTS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; METABOLISM; MIDDLE AGED; SPERM; VIROLOGY; VIRUS LOAD;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; CEREBROSPINAL FLUID; DRUG SUBSTITUTION; HIV INFECTIONS; HIV-1; HUMANS; MALE; MIDDLE AGED; NEVIRAPINE; NITRILES; PYRIMIDINES; RILPIVIRINE; SEMEN; VIRAL LOAD;

EID: 84903898568     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dku018     Document Type: Article

References (21)

1. Janssen-Cilag. Edurant (Rilpivirine) 25 mg Tablets, Summary of Product Characteristics. 2012. http://www.medicines.org.uk/EMC/medicine/25490/SPC/Edurant_25+mg/(24 December 2013, date last accessed).
2. European Medicines Agency. Edurant (Rilpivirine), CHMP Assessment Report. 2011. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002264/WC500118872.pdf (24 December 2013, date last accessed).
3. Crauwels H, Vingerhoets J, Ryan R et al. Pharmacokinetic parameters of once-daily rilpivirine following administration of efavirenz in healthy subjects. Antivir Ther 2012; 17: 439-46.
4. d'Arminio Monforte A, Cinque P, Mocroft A et al. Changing incidence of central nervous system diseases in the EuroSIDA cohort. Ann Neurol 2004; 55: 320-8.
5. Cysique LA, Vaida F, Letendre S et al. Dynamics of cognitive change in impaired HIV-positive patients initiating antiretroviral therapy. Neurology 2009; 73: 342-8.
6. Marra CM, Zhao Y, Clifford DB et al. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. AIDS 2009; 23: 1359-66.
7. Robertson KR, Su Z, Margolis DM et al. Neurocognitive effects of treatment interruption in stable HIV-positive patients in an observational cohort. Neurology 2010; 74: 1260-6.
8. Antinori A, Perno CF, Giancola ML et al. Efficacy of cerebrospinal fluid (CSF)-penetrating antiretroviral drugs against HIV in the neurological compartment: different patterns of phenotypic resistance in CSF and plasma. Clin Infect Dis 2005; 41: 1787-93.
9. 50 for wild-type HIV. J Antimicrob Chemother 2011; 66: 354-7.
10. Tiraboschi JM, Niubo J, Vila A et al. Etravirine concentrations in CSF in HIV-infected patients. J Antimicrob Chemother 2012; 67: 1446-8.
11. Yilmaz A, Gisslen M, Spudich S et al. Raltegravir cerebrospinal fluid concentrations in HIV-1 infection. PLoS One 2009; 4: e6877.
12. Else LJ, Taylor S, Back DJ et al. Pharmacokinetics of antiretroviral drugs in anatomical sanctuary sites: the male and female genital tract. Antivir Ther 2011; 16: 1149-67.
13. Else L, Watson V, Tjia J et al. Validation of a rapid and sensitive high-performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS) assay for the simultaneous determination of existing and new antiretroviral compounds. J Chromatogr B Analyt Technol Biomed Life Sci 2010; 878: 1455-65.
14. Watson V, Mora-Peris B, Tjia J et al. Rilpivirine concentrations in seminal plasma in HIV infected patients. In: Abstracts of the Fourteenth International Workshop on Clinical Pharmacology of HIV, Amsterdam, The Netherlands, 2013. Abstract P_17, p. 47.
15. Watson V, Tjia J, Szwandt S et al. Development and validation of a LC-MS/MS assay to quantify 10 anti-retroviral (ARV) drugs in cerebral spinal fluid (CSF). In: Abstracts of the Thirteenth International Workshop on Clinical Pharmacology of HIV, Barcelona, Spain, 2012. Abstract P_26, pp. 49-50.
16. Azijn H, Tirry I, Vingerhoets J et al. TMC278, a next-generation nonnucleoside reverse transcriptase inhibitor (NNRTI), active against wild-type and NNRTI-resistant HIV-1. Antimicrob Agents Chemother 2010; 54: 718-27.
17. de Vries-Sluijs TE, Dieleman JP, Arts D et al. Low nevirapine plasma concentrations predict virological failure in an unselected HIV-1-infected population. Clin Pharmacokinet 2003; 42: 599-605.
18. Veldkamp AI, Weverling GJ, Lange JM et al. High exposure to nevirapine in plasma is associated with an improved virological response in HIV-1-infected individuals. AIDS 2001; 15: 1089-95.
19. Enting RH, Hoetelmans RM, Lange JM et al. Antiretroviral drugs and the central nervous system. AIDS 1998; 15: 1941-5.
20. Poveda E, de Mendoza C, Pattery T et al. Phenotypic impact of resistance mutations on etravirine susceptibility in HIV patients with prior failure to nonnucleoside analogues. AIDS 2008; 22: 2395-8.
21. Tiraboschi JM, Niubo J, Ferrer E et al. Etravirine concentrations in seminal plasma in HIV-infected patients. J Antimicrob Chemother 2013; 68: 184-7.